RxDoctor Payments Data

Lynn Armah

Psychiatric/Mental Health · Oklahoma City, OKNPI 1841851672

Payments from drug & device makers

$2,563in general payments, 2019–2025

Across 53 payments — averaging $48.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$871
  • E.r. Squibb & Sons, L.L.C.$256
  • AbbVie$252
  • Otsuka America Pharmaceutical, Inc.$237
  • Neurocrine Biosciences, Inc.$210
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$127
  • plus $610 from 7 others

What the payments were for

  • Food & beverage$2,49897%
  • Education$653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,563 in reported general payments places this provider in the 70th percentile of 231 psychiatric/mental health providers in Oklahoma.

See all psychiatric/mental health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$3,495
Medicare patients
32
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate70$204,415
Invega TrinzaPaliperidone Palmitate21$150,773
Abilify MaintenaAripiprazole29$81,097
AustedoDeutetrabenazine16$77,998
VraylarCariprazine Hcl26$40,445
RexultiBrexpiprazole16$27,197
Clozapine OdtClozapine20$22,143
Paliperidone ErPaliperidone23$4,044
Clozapine38$3,479
Lurasidone Hcl22$3,296
Ziprasidone Hcl63$2,962
Atomoxetine Hcl29$2,468
Hydroxyzine Pamoate110$2,383
Buspirone Hcl124$1,800
Aripiprazole91$1,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$871$355,18991 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$237$108,29445 claims
Teva Pharmaceuticals USA, Inc.Austedo$117$77,99816 claims
AbbVieVraylar$252$40,44526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 231 psychiatric/mental health providers in Oklahoma.

Other psychiatric/mental health in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →